Entera Bio Q3 net loss $3.0M ($0.08/shr); cash $6.9M; awaits FDA SABRE ruling Jan 2025

Entera Bio Ltd.

2024-Q3 EPS reported $0.19 revenue$99,000

Net loss of $3.0M ($0.08 basic/diluted EPS) for Q3 2024 vs $2.4M ($0.08) in Q3 2023; operating expenses $3.0M vs $2.4M.
Cash and equivalents $6.9M; expects runway into Q3 2025.
EB613 (oral PTH) phase 3 prep ongoing; FDA decision on SABRE regulatory endpoint expected January 2025.
Oral GLP-1/glucagon (with OPKO) showed favorable PK/PD; plans to present at clinical conference.
Oral GLP-2 tablet for short bowel syndrome; final PK/PD data expected H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.